About Boan

Boan Biotech (6955.HK) is a fully-integrated biopharmaceutical company developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform, ADC Technology Platform and Cell Therapy Platform.

Boan Biotech operates across the entire value chain of the industry covering antibody discovery, cell line development, upstream and downstream process development, analytical and bio-analytical method development, technology transfer, non-clinical research, clinical research, regulatory affairs and registration, and commercial production. In the cell therapy field, Boan Biotech focuses on a new generation of enhanced and regulated CAR-T technology, developing safer, more effective, and affordable treatments for patients.

Boan Biotech’s portfolio includes three commercial products. Its pipeline includes multiple novel biologics as drug candidates protected for their international intellectual property rights and a number of biosimilar candidates. In addition to China, the company is also developing biopharmaceutical products in overseas markets, including the U.S. and the EU. With a differentiated portfolio and well-established commercial capabilities, Boan Biotech operates across the industry’s value chain from research and development to manufacturing and commercialization, laying a solid foundation for long-term, high-quality growth in the future.

China's Leading
Global Innovative Biopharmaceutical Company

Objectives

Short-term (2022)：
10 innovative biological products in clinical trialsand 1 biosimilar product launched in market
Mid-term (2025)：
2 innovative biological products, 4 biosimilar and 1 cell therapy products launched in market
Long-term (2030)：
5 innovative biological products launched in global markets

Diversified product line portfolio

Innovative Biological Product
Flagship

Concentrate resources on high priority products to accelerate development: Claudin 18.2, PD-L1/TGF-β, CD25, and CEA/CD3
Ensure clinical development are on-schedule for regular evaluation: CGRP, and IL4R
Achieve new target breakthroughs for long term growth and become “First in Class” globally
Biosimilar
Cornerstone

Concentrate resources on high priority products to early market launch: Bevacizumab, nivolumab, and denosumab (Xgeva) biosimilar
Ensure clinical development are on-schedule to market launch: Denosumab (Prolia), and dulaglutide
Advance low-priority products to phase 1 development and business partnering: Aflibercept, and secukinumab
Emerging Therapeutics
Specialisation

Concentrate resources for major R&D breakthrough in non-viral vectors / Solid tumor

Therapeutic Areas

Oncology (solid tumor)
Auto-immune diseases
Pain
Orthopaedics / Metabolism

Target Markets

Clinical development of biosimilar will progress simultaneously in China and key global markets. Innovative biologics and innovative therapeutics are focused on the domestic China market, with opportunities for global expansion.

Objectives Diversified product line portfolio Therapeutic Areas Target Markets

Our History

December—Boan Biotech was established in China

2013

January—Boan Biotech’s 200L pilot plant came into operation

2014

September—Investigational new drug (IND) of BA1101 was approved in China

November—Obtained the patent for “a preparation method of transgenic animal expressing human antibody” in China

2016

April—BA1101 entered into Phase 1 clinical trial in China

May—Investigational new drug (IND) of BA6101 was approved in China

June—Investigational new drug (IND) of BA1102 was approved in China

December—BA1101 entered into Phase 3 clinical trial in China

December—BA6101 entered into Phase 1 clinical trial in China

2017

March—Investigational new drug (IND) of BA9101 was approved in China

June—BA6101 entered into Phase 3 clinical trial in China

June—BA9101 entered into Phase 1 clinical trial in China

2019

February—Boan Biotech became a subsidiary of Luye Pharma, which, through its wholly-owned subsidiary, acquired 98% equity interest in Boan Biotech

June—Investigational new drug (IND) of BA6101 was approved in the US

October—Clinical trial application of BA6101 was approved in Germany

2020

January—BA1102 entered into Phase 3 clinical trial

January—Boan Biotech completed its first round of fund raising —Series A Investments, raising gross proceeds of approximately RMB876 million in aggregate

February—BA9101 entered into Phase 3 clinical trial

April—BA1101 was approved by the NMPA to launch in China

May—LY-CovMab completed its Phase 1 clinical trial

2021

September—Boan Biotech completed a further round of fund raising — Series B Investments, raising gross proceeds of approximately RMB210.9 million in aggregate

September—Investigational new drug (IND) of BA5101 was approved in China

September—Investigational new drug (IND) of BA1105 was approved in China

October—The application for the marketing authorization for BA6101 was accepted by the NMPA

December—Investigational new drug (IND) of BA1201 was approved in China

2021

February-BA5101 entered into formal trial of the Phase 1 clinical trial in China

July-BA5101 entered into Phase 3 clinical trial in China

September-BA-CovMab IND approved in China

September-BA1106 IND approved in China

October-BA2101 IND approved in China

November-BA6101 received the regulatory approval to commence commercialization in China

December-Boan Biotech was listed on the main board of the Hong Kong Stock Exchange

2022

Jan: cooperation with CP Qingdao for the commercialization of Boyoubei in China

Mar: Boluojia (BA1102) BLA accepted in China

Mar: BA9101 completed Phase III clinical trial enrolment in China

Apr: Boyounuo BLA accepted in Brazil

May: BA6101&BA1102 initiated international multicenter Phase III Clinical Trial

May: BA5101 completed Phase III clinical trial enrolment in China

Oct: BA1104 initiated Phase III clinical trials in China

Nov: BA2101 completed Phase I clinical trials in China

2023

Boan’s Boluojia® (Denosumab) Approved for Marketing in China

2024

Jiang Hua

Chairlady and Chief Executive officer

Dou Changlin

President of R&D and Chief Operating Officer

Chi Guangming

VP of Business Operation Center

Wang Shenghan

Chief Financial Officer

Lu Jun

Head of Quality Control

You Chunna

SVP of R&D Center

Zhou Ming

Chief Medical Officer

Song Deyong

Head of Biopharmaceutical Research and Discovery Department

Responsibility

All staff adhere to the company's environmental and occupational health and safety policy, objectives and commitments, with first-class management, excellent products and satisfactory services, and constantly provide high-tech products to serve the market.

EHS Responsibility
Welfare Project

EHS Resposibility
EHS Policy, Objectives and Commitments

EHS Policy
Focus on environment, health and safety to ensure sustainable development.

EHS objectives
Ensuring the integrated management system of environmental and occupational health and safety running in a normal way and improving it continuously.

EHS Commitments
Maintain the management system, take effective measures for continuous improvement, and correct and prevent any deviation from the environmental and occupational health and safety policy, and environmental and occupational health and safety objectives.
To ensure that all the employees strictly follow the company's environmental and occupational health and safety policy, objectives and commitments, with first-class management, quality products and satisfactory service to continuously provide high-tech products to serve the market.

LEARN MORE

China's leading global Biopharmaceuticals Innovative enterprise

About Boan

China's Leading Global Innovative Biopharmaceutical Company

Objectives

Short-term (2022)：

Mid-term (2025)：

Long-term (2030)：

Diversified product line portfolio

Innovative Biological Product

Biosimilar

Emerging Therapeutics

Therapeutic Areas

Target Markets

Culture

Philosophy

Core Values

Our History

2013

2014

2016

2017

2019

2020

2021

2021

2022

2023

2024

Our Team

Jiang Hua

Dou Changlin

Chi Guangming

Wang Shenghan

Lu Jun

You Chunna

Zhou Ming

Song Deyong

Scientific Advisory Committee

Liang Peng

Luo Shun

Paul Parren

Patricia Mucci LoRusso

Ma Jing

Dong Chen

Responsibility

Contact us

About Us

R&D

Products

News

Careers

Investors

China's leading global
Biopharmaceuticals
Innovative enterprise

China's Leading
Global Innovative Biopharmaceutical Company